FDA Warns 12 More GLP-1 Compounders (March 2026 Update)
The FDA's March 2026 enforcement wave adds 12 new compounding pharmacies to the warning list, bringing the total past 40 since late 2025. Here's who was flagged.
The FDA expanded its enforcement actions against unauthorized GLP-1 compounding facilities in March 2026, issuing warning letters to 12 additional pharmacies. Several of them supplied named telehealth platforms — patient-facing impact is significant.
Key takeaways
- Warning letters do not require immediate facility shutdown but signal regulatory escalation
- Several telehealth platforms have switched compounding partners in response
- Patients should verify their pharmacy's LegitScript status before refilling
- Compounded medication prices may rise as supply consolidates among compliant facilities
What the FDA is targeting
The agency's focus has been on facilities operating outside the 503A pharmacy framework, those marketing compounded medications as equivalent to FDA-approved drugs, and those without verifiable licensing.
Most major telehealth platforms in our review use 503A-licensed compounding pharmacies and were not directly affected. A handful of smaller platforms have rotated suppliers in the last 60 days.
How to verify your provider's pharmacy
LegitScript certification is a public record. The provider's review page on our site lists the pharmacy partner where disclosed; you can also ask any provider directly for the dispensing pharmacy's name and license number, which should be answered without resistance.
Treat reluctance to disclose this information as a meaningful warning signal.